 Home > Active Ingredient News > Antitumor Therapy > Imfinzi combined with tremelimumab in the treatment of liver cancer, phase III trial shows that it can improve overall survival

Imfinzi combined with tremelimumab in the treatment of liver cancer, phase III trial shows that it can improve overall survival

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

lead 4 sulfide

hepatocellular carcinoma diagnosis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

AstraZeneca's drug combination Imfinzi combined with tremelimumab has been shown to significantly improve the overall survival of patients with first-line unresectable liver cancer
.

The positive high-level results showed that tremelimumab added to Imfinzi showed a statistically and clinically significant improvement in overall survival compared to sorafenib

Infection of non-alcoholic fatty liver

HCC is the most common type of liver cancer, the third leading cause of cancer deaths, and the sixth most common cancer in the world
.

Approximately 900,000 people are diagnosed with liver cancer every year , and only 7% of advanced patients can survive for five years

diagnosis

Tremelimumab is a human monoclonal antibody and a potential new drug that can target cytotoxic T lymphocyte-associated protein 4 (CTLA-4)
.

Tremelimumab blocks the activity of CTLA-4, promotes T cell activation, triggers an immune response to cancer and promotes cancer cell death

immunity

Ghassan Abou-Alfa, MD, MBA, attending physician at Memorial Sloan Kettering Cancer Center and lead investigator of the HIMALAYA Phase III trial said: "HIMALAYA is the first to add a new single-priming dose of anti-CTLA4 antibody to another A phase III clinical trial of checkpoint inhibitors for the treatment of HCC
.

Anti-CTLA4 antibodies can help enhance the patient’s own immune response to liver cancer, aiming to maximize long-term survival while minimizing side effects

Data from the HIMALAYA Phase III trial will be announced at an upcoming medical conference

Both Imfinzi and tremelimumab received orphan drug designation for the treatment of HCC in the United States in 2020, while the latter received orphan drug designation in the European Union in the same year

Original source:

http:// href="http://" target="_blank" rel="noopener">http:// http:// leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.